Novel potential neuroprotective agents with both iron chelating and amino acid-based derivatives targeting central nervous system neurons

Biochemical Pharmacology

Volumn 70, Issue 11, 2005, Pages 1642-1652

  Zheng, Hailin ^a   Youdim, Moussa B H ^b   Weiner, Lev M ^a   Fridkin, Mati ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Antioxidant; Iron chelator; Lipid peroxidation; Neurodegenerative diseases; Neuroprotection; Oxidative stress

Indexed keywords

3 (8 HYDROXYQUINOLIN 5 YL)ALANINE; 4 (2 HYDROXYETHYL) 1 PIPERAZINEETHANESULFONIC ACID; AMINO ACID DERIVATIVE; ANTIPARKINSON AGENT; BUFFER; DEFEROXAMINE MESYLATE; HYDROGEN PEROXIDE; IRON; IRON CHELATING AGENT; NEUROPROTECTIVE AGENT; OXIDOPAMINE; RASAGILINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CELL DEATH; CELL PROTECTION; CELL STRAIN; CENTRAL NERVOUS SYSTEM; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; DRUG SYNTHESIS; ELECTRON SPIN RESONANCE; IC 50; IRON CHELATION; LIPID PEROXIDATION; NERVE CELL; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT;

ALANINE; AMINO ACIDS; ANIMALS; APOPTOSIS; CULTURE MEDIA, SERUM-FREE; DRUG EVALUATION, PRECLINICAL; FREE RADICAL SCAVENGERS; HYDROXYDOPAMINES; HYDROXYL RADICAL; HYDROXYQUINOLINES; IRON; IRON CHELATING AGENTS; LIPID PEROXIDATION; MOLECULAR STRUCTURE; NEURONS; NEUROPROTECTIVE AGENTS; PC12 CELLS; RATS;

EID: 27544471828     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2005.09.003     Document Type: Article

References (68)

1. I. McDowell Alzheimer's disease: insights from epidemiology Aging 13 2001 143 162
2. B. Drukarch, and F.L. van Muiswinkel Drug treatment of Parkinson's disease. Time for phase II Biochem Pharmacol 59 2000 1023 1031
3. S.B. Dunnett, and A. Bjorklund Prospects for new restorative and neuroprotective treatments in Parkinson's disease Nature 399 1999 A32 A39
4. S. Mandel, E. Grunblatt, P. Riederer, M. Gerlach, Y. Levites, and M.B.H. Youdim Neuroprotective strategies in Parkinson's disease: an update on progress NS Drugs 17 2003 729 762
5. C.K. Sen Redox signaling and the emerging therapeutic potential of thiol antioxidants Biochem Pharmacol 55 1998 1747 1758
6. Y. Gilgun-Sherki, E. Melamed, and D. Offen Oxidative stress induced-neurodegenerative diseases: the need for antioxidants that penetrate the blood-brain barrier Neuropharmacol 40 2001 959 975
7. Y. Gilgun-Sherki, Z. Rosenbaum, E. Melamed, and D. Offen Antioxidant therapy in acute central nervous system injury: current state Pharmacol Rev 54 2002 271 284
8. L. Zecca, M.B. Youdim, P. Riederer, J.R. Connor, and R.R. Crichton Iron, brain, ageing and neurodegenerative disorders Nat Rev Neurosci 5 2004 863 873
9. M. Takanashi, H. Mochizuki, K. Yokomizo, N. Hattori, H. Mori, and Y. Yamamura Iron accumulation in the substantia nigra of autosomal recessive Juvenile parkinsonism (ARJP) Parkinson's Relat Disord 7 2001 311 314
10. K.A. Jellinger The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease Drugs Aging 14 1999 115 140
11. M.D. Shults, D.A. Pearce, and B. Imperiali Modular and tunable chemosensor scaffold for divalent zinc J Am Chem Soc 125 2003 10591 10597
12. G.K. Walkup, and B. Imperiali Stereoselective synthesis of fluorescent-amino acids containing oxine (8-hydroxyquinoline) and their peptide incorporation in chemosensors for divalent zinc J Org Chem 63 1998 6727 6731
13. M.P. Mattson Metal-catalyzed disruption of membrane protein and lipid signalling in the pathogenesis of neurodegenerative disorders Ann NY Acad Sci 1012 2004 37 50
14. S. Przedborski, and V.R. Jackson-Lewis ROS and Parkinson's disease: a view to a kill Oxidative Stress Dis 5 2000 273 290
15. J.C. Desport, and P. Couratier Oxidative stress in neurodegenerative diseases Nutr Clin Metab 16 2002 253 259
16. X. Huang, M.P. Cuajungco, C.S. Atwood, R.D. Moir, R.E. Tanzi, and I. Ashley Alzheimer's disease, β-amyloid protein and zinc J Nutr 130 2000 1488S 1492S
17. C.A. Rottkamp, A.K. Raina, X. Zhu, E. Gaier, A.I. Bush, and C.S. Atwood Redox-active iron mediates amyloid-β toxicity Free Radic Biol Med 30 2001 447 450
18. S. Shoham, and M.B.H. Youdim Iron involvement in neural damage and microgliosis in models of neurodegenerative diseases Cell Mol Biol 46 2000 743 760
19. D. Ben-Shachar, G. Eshel, J.P. Finberg, and M.B.H. Youdim The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons J Neurochem 56 1991 1441 1444
20. J. Lan, and D.H. Jiang Desferrioxamine and Vitamin E protect against iron and MPTP-induced neurodegeneration in mice J Neural Transm 104 1997 469 481
21. D. Kaur, F. Yantiri, S. Rajagopalan, J. Kumar, J.Q. Mo, and R. Boonplueang Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease Neuron 37 2003 899 909
22. R.A. Cherny, C.S. Atwood, M.E. Xilinas, D.N. Gray, W.D. Jones, and C.A. McLean Treatment with a copper-zinc chelator markedly and rapidly inhibits β-amyloid accumulation in Alzheimer's disease transgenic mice Neuron 30 2001 665 676
23. K. Arasaki, and T. Nakanishi Selective neurotoxicity of clioquinol on the function of the posterior column nuclei Neurosci Lett 107 1989 85 88
24. J.B. Porter, and E.R. Huens The toxic effects of desferrioxamine Bailliere's Clin Haematol 2 1989 459 474
25. S. Singh, H. Khodr, M.I. Taylor, and R.C. Hider Therapeutic iron chelators and their potential side effects Biochem Soc Symp 61 1996 127 137
26. P.C. Waldmeier, A.M. Buchle, and A.F. Steulet Inhibition of catechol-O-methyltrans-ferase (COMT) as well as tyrosine and tryptophane hydroxylase by the orally active iron chelator, 1,2-dimethyl-3-hydroxypyridin-4- one (L1, CP20), in rat brain in vivo Biochem Pharmacol 45 1993 2417 2424
27. Warshawsky A, Ben-Shachar D, Youdim MBH. Pharmaceutical compositions comprising iron chelators for the treatment of neurodegenerative disorders and some novel iron chelators. International application published under the patent cooperation treaty; 2000 [International Publication Number WO 00/74664 A2].
28. Warshawsky A, Youdim MBH, Fridkin M, Zheng H, Warshawsky R. Preparation of neuroprotective iron chelators and pharmaceutical compositions comprising them; 2004 [Int. Publication Number WO 2004041151, A2 20040521].
29. D. Ben-Shachar, N. Nava Kahana, V. Kampel, A. Warshawsky, and M.H.B. Youdim Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxy-dopamine lession in rats Neuropharmacol 46 2004 254 263
30. H. Zheng, L.M. Weiner, O. Bar-Am, M. Epsztejn, I. Cabantchik, and A. Warshawsky Design, synthesis and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in neurodegenerative diseases Bioorg Med Chem 13 2005 773 783
31. J.B.M.M. van Bree, K.L. Audus, and R.T. Borchardt Carrier-mediated transport of baclifen across monolayers of bovine brain endothelial cells in primary culture Pharm Res 5 1988 369 371
32. Y. Takada, D.T. Vistica, N.H. Greig, D. Purdon, S.I. Rapoport, and Q.R. Smith Rapid high-affinity transport of a chemotherapeutic amino acid across the blood-brain barrier Cancer Res 52 1992 2191 2196
33. N.H. Greig, S. Momma, D.J. Sweeney, Q.R. Smith, and S.I. Rapoport Facilitated transport of melphalan at the rat blood-brain barrier by the large neutral amino acid carrier system Cancer Res 47 1987 1571 1576
34. J.H. Li, C.F. Bigge, R.M. Williamson, S.A. Borosky, M.G. Vartanian, and D.F. Ortwine Potent, orally active, competitive N-methyl-d-aspartate (NMDA) receptor antagonists are substrates for a neutral amino acid uptake system in Chinese hamster ovary cells J Med Chem 38 1995 1955 1965
35. 2 radicals with nitrones in the ultraviolet photolysis of aqueous hydrogen peroxide solutions Can J Chem 52 1974 3549 3553
36. M. Gassen, Y. Glinka, B. Pinchasi, and M.B.H. Youdim Apomorphine is a highly potent free radical scavenger in rat brain mitochondrial fraction Eur J Pharmacol 308 1996 219 225
37. P. Job Formation and stability of inorganic complexes in solution Ann Chim 9 1928 113 203
38. R. Foley, and R.C. Anderson Spectrophotometric studies of complex formation with sulfosalicylic acid. II. With uranyl ion J Am Chem Soc 71 1949 909 912
39. H. Zheng, S. Gal, L.M. Weiner, O. Bar-Am, A. Warshawsky, and M. Fridkin Novel multifunctional neuroprotective iron chelator-monoamine oxidase drugs for neurodegenerative diseases. I. In vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition J Neurochem 95 2005 68 78
40. S. Gal, H. Zheng, M. Fridkin, and M.B.H. Youdim Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. II. In vivo selective brain monoamine oxidase inhibition and neuro-protective activity J Neurochem 95 2005 79 88
41. L.M. Weiner Quantitative determination of thiol groups in low and high molecular weight compounds by electron paramagnetic resonance Meth Enzymol 251 1995 87 105
42. A. Rukenstein, R.E. Rydel, and L.A. Greene Multiple agents rescue PC12 cells from serum-free cell death by translation- and transcription-independent mechanisms J Neurosci 11 1991 2552 2563
43. L.A. Greene Nerve growth factor prevents the death and stimulates the neuronal differentiation of clonal PC12 pheochromocytoma cells in serum-free medium J Cell Biol 78 1978 747 755
44. M.B.H. Youdim, and M. Weinstock Novel neuroprotective anti-Alzheimer drugs with anti-depressant activity derived from the anti-Parkinson drug, rasagiline Mech Aging Dev 123 2002 1081 1086
45. B. Halliwell Reactive oxygen species and the central nervous system J Neurochem 59 1992 1609 1623
46. J.T. Rogers, J.D. Randall, C.M. Cahill, P.S. Eder, X.D. Huang, and H. Hiromi Gunshin An iron-responsive element type II in the 5′-untranslated region of the Alzheimer's amyloid precursor protein transcript J Biol Chem 277 2002 45518 45528
47. S. Hunot, B. Brugg, D. Ricard, P.P. Michel, M.P. Muriel, and M. Merle Ruberg Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of Patients with Parkinson disease Proc Natl Acad Sci USA 94 1997 7531 7536
48. M.A. Lovell, J.D. Robertson, W.J. Teesdale, J.L. Campbell, and W.R. Markesbery Copper, iron and zinc in Alzheimer's disease senile plaques J Neurol Sci 158 1998 47 52
49. S.W. Suh, K.B. Jensen, M.S. Jensen, D.S. Silva, J.P. Kesslak, and G. Danscher Histological evidence implicating zinc in Alzheimer's disease Brain Res 852 2000 274 278
50. A.I. Bush, W.H. Pettingell, G. Multhaup, M.D. Paradis, J.-P. Vonsattel, and K. Beyreuther Rapid induction of Alzheimer A βamyloid formation by zinc Science 265 1994 1464 1467
51. M.A. Smith, G. Perry, P.L. Richey, L.M. Sayre, V.E. Anderson, and M.F. Beal Oxidative damage in Alzheimer's disease Nature 382 1996 120 121
52. S.A. Kretchmar Nguyen, A. Craig, and K.N. Raymond Transferrin: the role of conformational changes in iron removal by chelators J Am Chem Soc 115 1993 6758 6764
53. C. Atabay, C.M. Cagnoli, E. Kharlamov, M.D. Ikonomovic, and H. Manev Removal of serum from primary cultures of cerebellar granule neurons induces oxidative stress and DNA fragmentation: protection with antioxidants and glutamate receptor antagonists J Neurosci Res 43 1996 465 475
54. Y. Glinka, M. Gassen, and M.B.H. Youdim Mechanism of 6-hydroxydopamine neurotoxicity Adv Res Neurodegen 5 1997 55 66
55. D. Offen, I. Ziv, H. Sternin, E. Melamed, and A. Hochman Prevention of dopamine-induced cell death by thiol antioxidants: possible implications for treatment of Parkinson's disease Exp Neurol 141 1996 32 39
56. T.J. Chiou, and W.F. Tzeng The roles of glutathione and antioxidant enzymes in menadione-induced oxidative stress Toxicology 154 2000 75 84
57. D. Bebbington, N.J.T. Monck, S. Gaur, A.M. Palmer, K. Benwell, and V. Harvey 3,5-Disubstituted-4-hydroxyphenyls linked to 3-hydroxy-2-methyl-4(1H)- pyridinone: potent inhibitors of lipid peroxidation and cell toxicity J Med Chem 43 2000 2779 2782
58. E. Dailly, S. Urien, and J.P. Tillement Chain-breaking antioxidants and ferriheme bound drugs are synergistic inhibitors of erythrocyte membrane peroxidation Free Radic Res 28 1998 205 214
59. M. Ghaemy, and S. Fruzandeh Synergistic effects of some phosphites antioxidants used in polypropylene stabilization Iran Polym J 8 1999 51 59
60. F. Xi, and L.R.C. Barclay Cooperative antioxidant effects of ascorbate and thiols with di-tert-butylcatechol during inhibited peroxidation in solution and in sodium dodecyl sulfate (SDS) micelles Can J Chem 76 1998 171 182
61. Warshawsky A, Youdim M, Fridkin M, Zheng HL, Warshawsky R. Preparation of neuroprotective iron chelators and pharmaceutical compositions comprising them; 2004 [International Publication Number WO 2004041151 A2].
62. S. Epsztejn, O. Kakhlon, H. Glickstein, W. Breuer, and Z.I. Cabantchik Fluorescence analysis of the labile iron pool of mammalian cells Anal Biochem 248 1997 31 40
63. G. Zanninelli, H. Glickstein, W. Breuer, P. Milgram, P. Brissot, and R.C. Hider Chelation and mobilization of cellular iron by different classes of chelators Mol Pharmacol 51 1997 842 852
64. B.D. Anderson Prodrugs for improved CNS delivery Adv Drug Deliver Rev 19 1996 171 202
65. G. Walkinshaw, and C.M. Waters Neurotoxin-induced cell death in neuronal PC12 cells is mediated by induction of apoptosis Neuroscience 63 1994 975 987
66. E. Grunblatt, S. Mandel, and M.B.H. Youdim Neuroprotective strategies in Parkinson's disease using the models of 6-hydroxydopamine and MPTP Ann NY Acad Sci 899 2000 262 273
67. A. Schapira, G. Bate, and P. Kirkpatrick Fresh from the pipeline: rasagiline Nat Rev Drug Discov 4 2005 625 626
68. O. Rascol, D.J. Brooks, E. Melamed, W. Oertel, W. Poewe, and F. Stocchi Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting Effect in Adjunct Therapy with Rasagiline Given Once Daily, study): a randomized, double-blind, parallel-group trial Lancet 365 2005 947 954